A novel EGFR variant EGFRx maintains glioblastoma stem cells through STAT5
Neuro-Oncology · 2024
DOI: 10.1093/neuonc/noad153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Wei Huang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Anatomy, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Glioblastomas are universally lethal brain tumors containing tumor-propagating glioblastoma stem cells (GSCs). EGFR gene amplification or mutation is frequently detected in GBMs and is associated with poor prognosis. However, EGFR variants in GSCs and their role in the maintenance of GSCs and progression of GBM are unclear.
Methods
EGFR variants were detected through bioinformatic HISAT-StringTie-Ballgown pipeline and verified through 5ʹ RACE, RT-PCR, ribonuclease protection, and northern blotting assays. EGFRx function was investigated through neurosphere, cell viability, intracranial xenograft and RNA-seq assays. EGFRx-STAT5 signaling was investigated through western blotting, coimmunoprecipitation, immunofluorescence, luciferase reporter, RT-PCR and CUT&Tag assays.
Results
We identified a novel EGFR variant (EGFRx), that is specifically expressed in GSCs. Unlike the EGFRvIII variant, which lacks exons 2–7, EGFRx is characterized by the absence of exons 2–14, and encodes an EGFR protein that does not possess the entire extracellular ligand-binding domain. We observed that EGFRx exhibits significant glycosylation, is required for GSC self-renewal, proliferation, and tumorigenesis, and highly active in glioblastomas compared to normal brain tissue. Mechanistically, EGFRx constitutively and specifically activates STAT5 in GSCs through spontaneous asymmetric dimerization of the kinase domain.
Conclusions
EGFRx plays essential roles in the maintenance of the GSC phenotype through constitutive activation of STAT5 and promotes GBM progression, suggesting that EGFRx-STAT5 signaling represents a promising therapeutic target for GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Anatomy, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Wei Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Huang, W., Li, J., Zhu, H., Qin, X., Chen, C., Wang, B., Wei, J., Song, Y., Lu, X., Li, Z., Xia, W., He, A., Cheng, L., Yu, X., Shu, K., & Wang, W. (2024). A novel EGFR variant EGFRx maintains glioblastoma stem cells through STAT5. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad153
Vancouver
Huang W, Li J, Zhu H, Qin X, Chen C, Wang B, et al. A novel EGFR variant EGFRx maintains glioblastoma stem cells through STAT5. Neuro-Oncology. 2024. doi:10.1093/neuonc/noad153
BibTeX
@article{Huang2024,
author = {Huang, Wei and Li, Jing and Zhu, Hongtao and Qin, Xuhui and Chen, Chao and Wang, Bing and Wei, Jinxia and Song, Yanyang and Lu, Xia and Li, Zhongyu and Xia, Wenqing and He, Aodi and Cheng, Lidong and Yu, Xingjiang and Shu, Kai and Wang, Wei},
title = {A novel EGFR variant EGFRx maintains glioblastoma stem cells through STAT5},
journal = {Neuro-Oncology},
year = {2024},
doi = {10.1093/neuonc/noad153}
}
EUVIMED